GSK Statistics
Total Valuation
GSK has a market cap or net worth of $75.13 billion. The enterprise value is $91.19 billion.
Important Dates
The next confirmed earnings date is Wednesday, April 30, 2025, before market open.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | Feb 21, 2025 |
Share Statistics
GSK has 4.08 billion shares outstanding. The number of shares has increased by 0.75% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.08B |
| Shares Change (YoY) | +0.75% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.92B |
Valuation Ratios
The trailing PE ratio is 23.31 and the forward PE ratio is 8.31.
| PE Ratio | 23.31 |
| Forward PE | 8.31 |
| PS Ratio | 1.91 |
| Forward PS | 2.30 |
| PB Ratio | 4.59 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 10.94 |
| P/OCF Ratio | 9.16 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.76, with an EV/FCF ratio of 13.27.
| EV / Earnings | 28.29 |
| EV / Sales | 2.32 |
| EV / EBITDA | 8.76 |
| EV / EBIT | 11.78 |
| EV / FCF | 13.27 |
Financial Position
The company has a current ratio of 0.78, with a Debt / Equity ratio of 1.30.
| Current Ratio | 0.78 |
| Quick Ratio | 0.50 |
| Debt / Equity | 1.30 |
| Debt / EBITDA | 1.99 |
| Debt / FCF | 3.10 |
| Interest Coverage | 10.06 |
Financial Efficiency
Return on equity (ROE) is 22.80% and return on invested capital (ROIC) is 12.70%.
| Return on Equity (ROE) | 22.80% |
| Return on Assets (ROA) | 6.52% |
| Return on Invested Capital (ROIC) | 12.70% |
| Return on Capital Employed (ROCE) | 16.37% |
| Revenue Per Employee | $572,359 |
| Profits Per Employee | $46,973 |
| Employee Count | 68,629 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.58 |
Taxes
In the past 12 months, GSK has paid $658.51 million in taxes.
| Income Tax | 658.51M |
| Effective Tax Rate | 15.13% |
Stock Price Statistics
The stock price has decreased by -9.08% in the last 52 weeks. The beta is 0.30, so GSK's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -9.08% |
| 50-Day Moving Average | 37.56 |
| 200-Day Moving Average | 37.69 |
| Relative Strength Index (RSI) | 55.01 |
| Average Volume (20 Days) | 6,163,340 |
Short Selling Information
| Short Interest | 16.20M |
| Short Previous Month | 18.51M |
| Short % of Shares Out | 0.80% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.35 |
Income Statement
In the last 12 months, GSK had revenue of $39.28 billion and earned $3.22 billion in profits. Earnings per share was $0.78.
| Revenue | 39.28B |
| Gross Profit | 28.21B |
| Operating Income | 7.74B |
| Pretax Income | 6.06B |
| Net Income | 3.22B |
| EBITDA | 10.41B |
| EBIT | 7.74B |
| Earnings Per Share (EPS) | $0.78 |
Full Income StatementBalance Sheet
The company has $5.42 billion in cash and $21.27 billion in debt, giving a net cash position of -$15.85 billion or -$3.88 per share.
| Cash & Cash Equivalents | 5.42B |
| Total Debt | 21.27B |
| Net Cash | -15.85B |
| Net Cash Per Share | -$3.88 |
| Equity (Book Value) | 16.38B |
| Book Value Per Share | 4.19 |
| Working Capital | -5.88B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $8.21 billion and capital expenditures -$1.75 billion, giving a free cash flow of $6.87 billion.
| Operating Cash Flow | 8.21B |
| Capital Expenditures | -1.75B |
| Free Cash Flow | 6.87B |
| FCF Per Share | $1.68 |
Full Cash Flow StatementMargins
Gross margin is 71.81%, with operating and profit margins of 19.71% and 8.21%.
| Gross Margin | 71.81% |
| Operating Margin | 19.71% |
| Pretax Margin | 11.08% |
| Profit Margin | 8.21% |
| EBITDA Margin | 26.49% |
| EBIT Margin | 19.71% |
| FCF Margin | 17.49% |
Dividends & Yields
This stock pays an annual dividend of $1.55, which amounts to a dividend yield of 4.14%.
| Dividend Per Share | $1.55 |
| Dividend Yield | 4.14% |
| Dividend Growth (YoY) | 6.67% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 199.25% |
| Buyback Yield | -0.75% |
| Shareholder Yield | 3.38% |
| Earnings Yield | 4.29% |
| FCF Yield | 9.14% |
Dividend DetailsAnalyst Forecast
The average price target for GSK is $47.00, which is 25.35% higher than the current price. The consensus rating is "Hold".
| Price Target | $47.00 |
| Price Target Difference | 25.35% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 3.80% |
| EPS Growth Forecast (5Y) | 28.11% |
Stock ForecastsStock Splits
The last stock split was on July 19, 2022. It was a reverse split with a ratio of 0.8:1.
| Last Split Date | Jul 19, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.8:1 |
Scores
GSK has an Altman Z-Score of 1.81 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.81 |
| Piotroski F-Score | 6 |